Medicine
Prevduo 0.6 mg/3 mg per 3 mL injection
Prevduo 0.6 mg/3 mg per 3 mL injection is a prescription medicine containing Glycopyrrolate and Neostigmine methylsulfate for intravenous use, marketed by Endo, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store in carton until time of use.
Key facts
- Active ingredient (INN)
- Glycopyrrolate and Neostigmine methylsulfate
- Brand
- Prevduo
- Strength
- 0.6 mg/3 mg per 3 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 5 syringes of 3 mL
- Marketing authorisation holder
- Endo
- Manufacturer
- Endo
- Origin register
- US FDA, United States
- Storage
- Store in carton until time of use.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 May 2023
- Identifiers
- RxCUI 2637041, 2637047DailyMed set ID dd8ad38f-247b-4948-a13c-8f3a4921b4f1NDC 42023-269Application NDA216903
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 5 syringe, plastic in 1 carton / 3 mL in 1 syringe, plastic | 42023-269-05 | Endo | 15 May 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 23 February 2023 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Glycopyrrolate and Neostigmine methylsulfate is a fixed-dose combination of an anticholinergic, a cholinergic muscarinic antagonist and a cholinesterase inhibitor. It is available as injection for intravenous use. MedsAcross supplies Glycopyrrolate and Neostigmine methylsulfate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Glycopyrrolate and Neostigmine methylsulfateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- PREVDUO prescribing information (Endo) · U.S. National Library of Medicine, DailyMed
Need Prevduo 0.6 mg/3 mg per 3 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.